Transgene Bioteck Signs Licensing, Technology Transfer Agreement With Dr. Reddy’s

Transgene Bioteck (TBL) has signed a licensing and technology transfer agreement with Dr. Reddy’s Laboratories (DRL), Hyderabad, for the out licensing of a technology to be used for the manufacture of Orlistat.

As per the agreement, DRL will gain worldwide right to the technology for the manufacture and commercialization of Orlistat API, which was developed by TBL.

TBL will receive an upfront payment, additional payment for certain commercial milestone and royalties on the sale of Orlistat API in all countries worldwide.

Orlistat is a lipase inhibitor used for the obesity management that acts by preventing the absorption of fats from the human diet, thereby reducing caloric intake and is the most studied weight loss medicine in the world. It is used in the treatment of obesity including management of weight loss and weight maintenance. Orlistat is also known to reduce blood pressure and appear to prevent the onset of type 2 diabetes.